摘要
目的探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法选择2014年2月—2015年2月收治的60例精神分裂症患者作为研究对象,随机分为对照组和研究组各30例。对照组给予口服利培酮治疗,1 mg/次,1次/d,根据病情调整至2~3 mg/次,2次/d;研究组给予口服氨磺必利治疗,100 mg/次,1次/d,根据病情调整至200~600 mg/次,2次/d。两组均治疗8周。采用阳性与阴性症状量表（positive and negative symptoms scale,PANSS）评定临床疗效,不良反应量表（treatment emergent symptom scale,TESS）评定不良反应发生情况。计量资料组间比较采用t检验,组内比较采用配对t检验,计数资料采用χ2检验,P〈0.05为差异有统计学意义。结果治疗后研究组总有效率为93.3%,对照组为86.7%,两组比较差异无统计学意义（P〉0.05）。研究组与对照组治疗后2、4、8周PANSS得分分别为（71.5±17.1）、（59.8±14.4）、（47.1±10.1）、（72.6±17.5）、（60.2±15.2）、（48.3±13.9）分,均明显低于治疗前的（85.4±15.1）、（89.6±16.2）分,差异均有统计学意义（均P〈0.05）。研究组总不良反应发生率、锥体外系反应发生率分别为20.00%、0,显著低于对照组的46.67%、20.00%,差异均有统计学意义（均P〈0.05）。结论氨磺必利治疗精神分裂症疗效显著,与利培酮疗效相当,安全性高,患者依从性好,值得临床推广应用。
Objective To explore the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia.Methods 60 cases of patients with schizophrenia from February 2014 to February 2015 were selected,randomly divided into control group and treatment group（n=30）.Patients in the control group were treated with risperidone 1 mg/count,1 count/d,according to the condition adjustment to 2- 3 mg/count,2 counts/d.Patients in the treatment group treated with amisulpride 100 mg/count,1 count/d,according to the condition adjustment to 200- 600 mg/count,2 counts/d.All the groups were treated for 8 weeks.Use positive and negative symptoms scale（PANSS） to assess the clinical curative effect,treatment emergent symptom scale（TESS） to evaluate the adverse reaction.Measurement data between group was processed by t test,in group was processed by paired t test,count data was processed by chi square test,P〈0.05 was considered statistically significant.Results The total effective rate of treatment group was 93.3%,in control group was 86.7%,the difference between the two groups was not statistically significant（P〉0.05）.The PANSS score of the treatment group and control group after 2,4,8 weeks were（71.5±17.1）,（59.8±14.4）,（47.1±10.1）,（72.6±17.5）,（60.2±15.2）,（48.3±13.9）points,significantly lower than that before treatment[（85.4±15.1）,（89.6±16.2）points],the differences were statistically significant（all P〈0.05）.The total adverse reaction rate and extrapyramidal reaction rate of treatment group were 20.00% and 0,significantly lower than that of the control group（46.67%,20.00%）,the differences were statistically significant（all P〈0.05）.Conclusion Amisulpride has an evident effect equivalent to risperidone,high safety and better compliance in the treatment of schizophrenia.
出处
《社区医学杂志》
2015年第17期4-6,共3页
Journal Of Community Medicine
关键词
精神分裂症
氨磺必利
利培酮
阳性与阴性症状量表
不良反应量表
Schizophrenia
Amisulpride
Risperidone
Positive and negative symptoms scale
Treatment emergent symptom scale
